Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to evaluate the overall response rate of ibrutinib, as assessed by the Independent Review Committee (IRC), in subjects with MCL who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.
Critère d'inclusion
- Mantle cell lymphoma